Overview

Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-1811 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. This study will be conducted in 2 phases, Phase 1a (Part A and Part B: monotherapy) and Phase 1b (Part C: combination therapy), in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit (Phase 1a and Phase 1b) and whose diseases are indicated for pembrolizumab monotherapy treatment (Phase 1b only).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Pembrolizumab